DEFA14A ·Filed Apr 24, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-177401
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's 10-Q filing for any guidance revisions or disclosures related to the recent board changes. The resignation of two directors may signal governance shifts, but this proxy filing itself is routine.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
APGE ▲ +55.06% at T+60d
NEUTRAL call ✓ call won +55.06% · α vs SPY +50.28% · entry $86.47 → $134.08
Entry anchored
Apr 24, 03:59 PM ET
via exchange tick
T+1d
-1.27%
call -1.27% · α -0.79%
$85.37
settled 5mo ago
T+5d
-3.38%
call -3.38% · α -3.78%
$83.55
settled 5mo ago
T+20d
-4.23%
call -4.23% · α -9.19%
$82.81
settled 4mo ago
T+60d
+55.06%
call +55.06% · α +50.28%
$134.08
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Apogee Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class III directors, ratification of its auditor, and advisory approval of executive compensation. This routine proxy filing follows recent board resignations, suggesting potential governance changes, but the filing itself contains no new material information.

Key Facts

  • Annual shareholder meeting to vote on re-election of three Class III directors: Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr.
  • Vote to ratify Ernst & Young LLP as independent auditor.
  • Advisory vote to approve compensation of named executive officers.
  • Recent context: Two board members resigned effective May 11, 2026, just prior to this proxy filing.

Financial Impact

No material financial figures disclosed in this proxy statement.

Risk Factors

  • Potential for governance instability following the resignation of two board members.
  • No immediate financial risk indicated by this proxy filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177401
Document: 0001193125-26-177401-index-headers.html0001193125-26-177401
Document: 0001193125-26-177401-index.html0001193125-26-177401
Document: 0001193125-26-177401.txt0001193125-26-177401
31 reports for APGE
Performance horizon
93% Hit rate 14 of 15 directional calls best @ T+60▲ +73.31%May 27, 2026
Filters
Rows
Reports for APGE — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
15-12G
NEUTRAL ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
25-NSE
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Sep 3, 2026
29d ago
8-K
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$134.55 $134.71▲ +0.12%▲ +0.56%—
Aug 10, 2026
7w ago
8-K
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 10, 2026
7w ago
Press Release
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 6, 2026
8w ago
Institutional Cluster
MIXED ★ 5/10
$134.49 $134.45▼ −0.03%▼ −1.24%—
Aug 3, 2026
8w ago
DEFA14A
BULLISH ★ 5/10
$134.19 $134.69▲ +0.37%▲ +0.47%—
Jul 11, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$133.82 $134.00▲ +0.13%▲ +0.92%—
Jun 26, 2026
13w ago
DEFA14A
BULLISH ★ 6/10
$132.61 $133.50▲ +0.67%▼ −0.72%—
Showing 10 of 31

US Market Status

Market Open — Closes in 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access